All Updates

All Updates

icon
Filter
M&A
2seventy bio divests hemophilia A program to Novo Nordisk in asset purchase agreement
Human Gene Editing
Jun 27, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Human Gene Editing

Human Gene Editing

Jun 27, 2024

2seventy bio divests hemophilia A program to Novo Nordisk in asset purchase agreement

M&A

  • US biotech company 2seventy bio sold its hemophilia A program, along with rights to some of its gene-editing tech to Denmark-based pharmaceutical company Novo Nordisk. The transaction was valued at USD 40 million approximately.

  • This agreement grants Novo Nordisk access to 2seventy's hemophilia A treatment, as well as transfer of its in vivo gene-editing technology, including megaTAL technology, for non-oncology and non-autoimmune disease-related projects. Two of the staff members who were working on the hemophilia A program will also move to Novo Nordisk.

  • 2seventy plans to focus exclusively on the development and commercialization of its multiple myeloma treatment Abecma (idecabtagene vicleucel), a BCMA-targeted CAR T-cell therapy.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.